Dai Yunkai, Zhang Yunzhan, Li Danyan, Ye Jintong, Chen Weijing, Hu Ling
Institute of Gastroenterology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Evid Based Complement Alternat Med. 2017;2017:9591319. doi: 10.1155/2017/9591319. Epub 2017 Feb 19.
Modified Banxia Xiexin decoction (MBXD) is a classical Chinese herbal formula in treating gastroesophageal reflux disease (GERD) for long time, but the efficacy of it is still controversial. This study is to evaluate the efficacy and safety of MBXD for the treatment of GERD in adults. The search strategy was carried out for publications in seven electronic databases. RevMan software version 5.3 and the Cochrane Collaboration's risk of bias tool were performed for this review. Twelve RCTs were included for the analysis. The results of overall clinical efficacy and efficacy under gastroscope demonstrated that MBXD was superior to conventional western medicine. Meanwhile, the results of subgroup analysis showed clinical heterogeneity between the two groups. However, there was no statistically significant difference in acid regurgitation between the two groups. But in the improvement of heartburn and sternalgia, the results showed statistically significant differences for the comparison between two groups. In addition, the adverse reactions of the experiment groups were not different from those of the control groups. This systematic review indicates that MBXD may have potential effects on the treatment of patients with GERD. But because the evidence of methodological quality and sample sizes is weak, further standardized researches are required.
半夏泻心汤加减（MBXD）是长期用于治疗胃食管反流病（GERD）的经典中药方剂，但其疗效仍存在争议。本研究旨在评估MBXD治疗成人GERD的疗效和安全性。检索了七个电子数据库中的相关出版物。使用RevMan 5.3软件和Cochrane协作网偏倚风险工具进行本综述。纳入12项随机对照试验进行分析。总体临床疗效和胃镜下疗效结果表明，MBXD优于传统西药。同时，亚组分析结果显示两组间存在临床异质性。然而，两组间反酸情况无统计学显著差异。但在改善烧心和胸骨后疼痛方面，两组比较结果显示有统计学显著差异。此外，试验组的不良反应与对照组无差异。本系统评价表明，MBXD可能对GERD患者的治疗有潜在作用。但由于方法学质量和样本量的证据不足，需要进一步进行规范研究。
